MARKET

OTLK

OTLK

Outlook Therapeutics Inc
NASDAQ
1.270
+0.010
+0.79%
Closed 19:08 02/07 EST
OPEN
1.250
PREV CLOSE
1.260
HIGH
1.290
LOW
1.220
VOLUME
710.47K
TURNOVER
--
52 WEEK HIGH
2.120
52 WEEK LOW
0.6839
MARKET CAP
325.97M
P/E (TTM)
-4.0797
1D
5D
1M
3M
1Y
5Y
Outlook draws bullish views at Cantor on potential FDA nod for lead asset
Seeking Alpha · 1d ago
SPCE, AI and EXPR are among pre market gainers
Seeking Alpha · 2d ago
Cantor Fitzgerald Initiates Coverage On Outlook Therapeutics with Overweight Rating, Announces Price Target of $4
Benzinga · 2d ago
--Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target
--Cantor Fitzgerald Initiates Outlook Therapeutics at Overweight With $4 Price Target
MT Newswires · 2d ago
BRIEF-Outlook Therapeutics® Strengthens Medical Affairs And Commercial Expertise With Appointments Of Surendra Sharma, MD, Senior Vice President Of Medical Affairs And Glen Olsheim, Executive Director Of Commercial Excellence
Reuters · 01/19 14:00
HC Wainwright & Co. Maintains Buy on Outlook Therapeutics, Lowers Price Target to $5
Benzinga · 01/06 11:29
Outlook Therapeutics (OTLK) Receives a Buy from H.C. Wainwright
TipRanks · 01/06 11:15
HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating
HC Wainwright Adjusts Price Target on Outlook Therapeutics to $5 From $6, Maintains Buy Rating
MT Newswires · 01/06 09:54
More
About OTLK
Outlook Therapeutics, Inc. (Outlook) is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. Its clinical program for ONS-5010 in wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. Outlook sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets for the treatment of wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).

Webull offers kinds of Outlook Therapeutics Inc stock information, including NASDAQ:OTLK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTLK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTLK stock methods without spending real money on the virtual paper trading platform.